Novel, Potent, and Selective 5-HT3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies

Journal of Medicinal Chemistry
1995.0

Abstract

Synthesis and pharmacological evaluation of a series of condensed quinoline derivatives bearing a basic nitrogen on piperazine or [(dimethylamino)ethyl]thio moieties attached at the 2-position of the quinoline nucleus are described. 5-HT receptor binding studies revealed, for most of the compounds studied, nanomolar affinity for the 5-HT3 receptor subtype. The most active compound, benzopyrano[3,4-c]quinoline derivative 5f, displayed a Ki value very similar to that reported for quipazine along with an improved selectivity. Functional and in vivo testing carried out on three selected compounds showed that 5f,j,n are potent 5-HT3 receptor antagonists with potencies in the same range as the best known 5-HT3 receptor antagonists ondansetron, tropisetron, and zacopride. The crystal and molecular structures of compounds 5f,j,n were determined by single-crystal X-ray diffraction and used as starting structures for molecular modeling studies. Comparative molecular field analysis (CoMFA) was applied to binding constants of compounds 5a-p and 6a-h. The cross-validated r2, derived from partial least-squares calculations, indicated a good predictive capacity for affinity values in the series of compounds investigated. Evidence for the prediction capacity is provided in the form of plots of actual vs predicted pKi values. The steric and electrostatic features of the CoMFA-derived model are presented as standard coefficient contour maps of steric and electrostatic fields.

Knowledge Graph

Similar Paper

Novel, Potent, and Selective 5-HT3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies
Journal of Medicinal Chemistry 1995.0
Novel Potent and Selective Central 5-HT<sub>3</sub> Receptor Ligands Provided with Different Intrinsic Efficacy. 1. Mapping the Central 5-HT<sub>3</sub> Receptor Binding Site by Arylpiperazine Derivatives
Journal of Medicinal Chemistry 1998.0
Novel Potent and Selective Central 5-HT<sub>3</sub> Receptor Ligands Provided with Different Intrinsic Efficacy. 2. Molecular Basis of the Intrinsic Efficacy of Arylpiperazine Derivatives at the Central 5-HT<sub>3</sub> Receptors
Journal of Medicinal Chemistry 1999.0
Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT<sub>3</sub> Receptor Agonists:  Synthesis, Further Structure−Activity Relationships, and Biological Studies
Journal of Medicinal Chemistry 1999.0
Novel and Selective Partial Agonists of 5-HT<sub>3</sub> Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
Journal of Medicinal Chemistry 1997.0
Further Studies on the Interaction of the 5-Hydroxytryptamine<sub>3</sub>(5-HT<sub>3</sub>) Receptor with Arylpiperazine Ligands. Development of a New 5-HT<sub>3</sub>Receptor Ligand Showing Potent Acetylcholinesterase Inhibitory Properties
Journal of Medicinal Chemistry 2005.0
Novel and Highly Potent 5-HT<sub>3</sub> Receptor Agonists Based on a Pyrroloquinoxaline Structure
Journal of Medicinal Chemistry 1997.0
Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists
Journal of Medicinal Chemistry 1990.0
Novel, Potent, and Selective Quinoxaline-Based 5-HT<sub>3</sub>Receptor Ligands. 1. Further Structure−Activity Relationships and Pharmacological Characterization
Journal of Medicinal Chemistry 2009.0
Structure−Activity Relationships for the Binding of Arylpiperazines and Arylbiguanides at 5-HT<sub>3</sub>Serotonin Receptors
Journal of Medicinal Chemistry 1996.0